WAVE Life Sciences (WVE)
(Delayed Data from NSDQ)
$8.19 USD
+2.85 (53.37%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $7.88 -0.31 (-3.79%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
WAVE Life Sciences Ltd. [WVE]
Reports for Purchase
Showing records 1 - 20 ( 61 total )
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Single Injection of WVE-007 with Sema Doubles Weight Loss?Thoughts on INHBE Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Reduction in NfL Along with mHTT Silencing Important for Accelerated Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
The Future of Obesity Therapeutics-Takeaways from European Obesity Conference in Venice
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
"FORWARD-53" (DMD) to Continued Upside "RestorAATion" (AATD)
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Human Genetics Backed INHBE Program is Promising; Reiterate Buy and Raising PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for WVE 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Part A Data Supportive of the Expectations Surrounding Superior Dystrophin Level Going FORWARD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Wave Interferes with Obesity-Our Insights on Inhibin betaE Biology
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
WVE-006 Might Define Wave?s Leadership in RNA Editing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
C9orf72 A Tough Nut to Crack-Thoughts on FOCUS-C9
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Sustained Dystrophin Levels with Longer Exposure of WVE-N531 Might be Key; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Focusing on WVE-N531 With Plans For Harnessing the Power of RNA Medicine; Reit. Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
WAVE Achieves POC Data in the Clinics?Thoughts on WVE-N531?s Trial Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
GSK Eyes On Oligonucleotides Through Wave?s PRISM
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Thoughts on the Upcoming Data Readout of WVE-N531; Reit. Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
RNA Editing, An Early But Compelling Approach in AATD?Initial Thoughts on WVE-006
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Wave''s HD Data Encouraging For the PRISM?Thoughts on the Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Thoughts on WVE-006?The Most Advanced ADAR Program Targeting AATD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
WVE-N531 Update Remains a Central Focus; Reit Buy and Lowering our PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A